Tag Archives: patients

New virus surge sends younger patients to Spain’s hospitals

BARCELONA, Spain — Julio Miranda had never felt the threat of the coronavirus too close. With an appointment for his first COVID-19 jab scheduled for mid-July, the 48-year-old house painter was, like many in the vaccine-abundant developed world, eagerly awaiting the end of his personal pandemic worries. Then a colleague fell ill last month, followed… Read More »

Gap in Breast Cancer Survival for Black, White Patients Shrinks, But Not by Enough

By Amy Norton HealthDay Reporter FRIDAY, July 2, 2021 — Racial disparities in breast cancer survival have narrowed in recent years, but Black women with the disease still have double the death rate of white women. That’s according to a study that tracked breast cancer trends in Florida between 1990 and 2015. Overall, deaths from… Read More »

Injectafer (ferric carboxymaltose injection) Receives FDA Approval for Single Dose Option for the Treatment of Adult Patients with Iron Deficiency Anemia

BASKING RIDGE, N.J. and SHIRLEY, N.Y., May 6, 2021 /PRNewswire/ — Daiichi Sankyo, Inc. and American Regent, Inc., a Daiichi Sankyo Group company, today announced that the U.S. Food and Drug Administration (FDA) has approved a single 1000 mg dose option of Injectafer® (ferric carboxymaltose injection), an iron replacement product, for the treatment of iron deficiency anemia (IDA) in adult… Read More »

New Blood Markers May Reveal Heart Attack in Chest Pain Patients, Find Researchers

Washington, April 23: A new study published in the open-access journal Frontiers in Cardiovascular Medicine identified telltale markers in the blood of heart attack patients that distinguished them from patients suffering chest pain with other causes. The researchers hope that the results will lead to new diagnostic tests for heart attacks. If you have ever… Read More »

FDA Approves Nulibry (fosdenopterin) to Reduce the Risk of Mortality in Patients with Molybdenum Cofactor Deficiency (MoCD) Type A

FDA Approves Nulibry (fosdenopterin) to Reduce the Risk of Mortality in Patients with Molybdenum Cofactor Deficiency (MoCD) Type A PALO ALTO, February 28, 2021 – BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio) and affiliate Origin Biosciences, Inc. (Origin) today announced the U.S. Food and Drug Administration (FDA) has approved Nulibry (fosdenopterin) for Injection as the first… Read More »